PDCD1 and melanoma: Compared with two previous studies (NCT02821000 and NCT02836795) of PD-1 blockade for treating melanoma patients, the data showed the ORR of two types of anti-PD-1 antibodies in mucosal subtype were 13.3% and 0, respectively (14, 55).